:::
顧正崙

顧正崙 / Dr. Cheng-Lung Ku

JobTitle: Distinguished professor; Director of CMCI

CurrentJob: CMCI

E-mail: clku@cgu.edu.tw

Phone: 03-211-8800 #3483

Education: PhD

Expertise: Anti-cytokine autoantibodies, hereditary immunodeficiency, cell therapy

Education and experience

Education
2007 PhD Immunology, Paris Descartes University
2000 MSc, Microbial Immunology, National Yang Ming Chiao Tung University
1998 BSc Animal Science and Technology, National Taiwan University, Department of Animal Science and Technology
 
Experience
2023-  Distinguished Professor, Graduate Institute of Clinical Medicine, Chang Gung University
2021-  Director, Center for Molecular and Clinical Immunology (CMCI), Chang Gung University
2018-  Founder and Executive Chairman, Formosa Immunology Spring School and Symposium (FISS)
2023-  Joint Appointment Professor, Department of Pediatrics, Linkou Chang Gung Memorial Hospital
2023-  Elixiron Therapeutic, Chief Scientist

Awards and honors

2022 Chang Gung University Excellent Teacher Research Award
2021 Ministry of Science and Technology Outstanding Research Award
2021 Chang Gung University Excellent Teacher Research Award
2020 Chang Gung University Excellent Teacher Technology Integration Award
2019 Ministry of Science and Technology Outstanding Contribution to Technology Transfer Award
2019 Chang Gung University Excellent Teacher Technology Integration Award
2019 Ministry of Science and Technology Excellent Young Scholar Research Project
2017 Academia Sinica Young Scholar Research Publication Award
2017 Chang Gung University Excellent Teacher Research Award
2016 Ministry of Science and Technology Wu Ta-You Award
2016 Immunology Society Outstanding Research Award
2016 Chang Gung University Excellent Teacher Research Award
2016 Ministry of Science and Technology Excellent Young Scholar Research Project

Research direction

Autoantibodies Against Cytokines and Human Diseases
Monoclonal B Cell Research
Cell Therapy

Selected research

  • Peng JJ, Wang L, LiZ, Ku CL*, Ho PC. Metabolic challenges and interventions in CAR T cell therapy. Sci Immunol. 2023. 8(82):eabq3016. doi:10.1126/sciimmunol.abq3016.
  • Ng CY, Chiu YC, Chan YP, Lin YJ, Chung PH, Chung WH, Ku CL*. Skin Interstitial Fluid and Plasma Multiplex Cytokine Analysis Reveals IFN-γ Signatures and Granzyme B as Useful Biomarker for Activity, Severity and Prognosis Assessment in Vitiligo. Front Immunol. 2022. 13(872458. doi:10.3389/fimmu.872458.
  • Shih HP, Ding JY, Bellón JS, Lo YF, Chung PH, Ting HT, Peng JJ, Wu TY, Lin CH, Lo CC, Lin YN, Yeh CF, Chen JB, Wu TS, Liu YM, Kuo CY, Wang SY, Tu KH, Ng CY, Lei WT, Tsai YH, Chen JH, Chuang YT, Huang JY, Rey FA, Chen HK, Chang TW, Piehler J, Chi CY, Ku CL*. Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response. J Exp Med. 2022. 219 (9): e20212126. 
  • Kuo CY, Ku CL*, Lim HK, Hsia SH, Lin JJ, Lo CC, Ding JY, Kuo RL, Casanova JL, Zhang SY, Chang LY*, Lin TY*. Life-Threatening Enterovirus 71 Encephalitis in Unrelated Children with Autosomal Dominant TLR3 Deficiency. J. Clin. Immunol. 2022. doi:10.1007/s10875-021-01170-9.
  • Shih HP, Ding JY, Yeh CF, Chi CY, Ku CL*. Anti-interferon-γ autoantibody-associated immunodeficiency. Curr. Opin. Immunol. 2021. 72:206-214.
  • Guo J#, Ning XQ#, Ding JY#, Zheng YQ#, Shi NN, Wu FY, Lin YK, Shih HP, Ting HT, Liang G, Lu XC, Kong JL, Wang K, Lu YB, Fu YJ, Hu R, Li TM, Pan KS, Li XY, Huang CY, Lo YF, Chang IY, Yeh CF, Tu KH, Tsai YH, Ku CL*, Cao CW*. Anti-interferon-γ autoantibodies underlie disseminated Talaromyces marneffei infections. J Exp Med. 2020. 217(12):e20190502. (#共同作者)
  • Ku CL*, Chi CY, von Bernuth H, and Doffinger R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum Genet. 2020. 139:783-794.
  • Kuo CY, Wang SY, Shih HP, Tu KH, Huang WC, Ding JY, Lin CH, Yeh CF, Ho MW, Chang SC, He CY, Chen HK, Ho CH, Lee CH, Chi CY and Ku CL*. Disseminated cryptococcosis due to anti-granulocyte-macrophage colony-stimulating factor autoantibodies in the absence of pulmonary alveolar proteinosis. J. Clin. Immunol. 2017, 37:143-152.
  • Lin CH, Chi CY, Shih HP, Ding CT, Wang SY, Kuo CY, Yeh CF, Tu KH, Liu SH, Ho MW, Chen CK, Ho CH, Lee CH, and Ku CL*. Identification of a Major Epitope by Anti-Interferon-γ Autoantibodies in Patients with Mycobacterial Disease. Nat Med. 2016, 22:994-1001. 
  • Ku CL*, Lin CH, Chang SW, Chu CC, Chan JF, Kong XF, Lee CH, Rosen EA, Ding JY, Lee WI, Bustamante J, Witte T, Shih HP, Kuo CY, Chetchotisakd P, Kiertiburanakul S, Suputtamongkol Y, Yuen KY, Casanova JL, Holland SM, Doffinger R, Browne SK, and Chi CY. Anti-IFN-γ autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia. J Aller Clin Immunol. 2016, 137:945-948.e948.
  •  Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, Lo WJ, Lin PC, Chen HJ, Chou CH, Feng JY, Fung CP, Sher YP, Li CY, Wang JH, and Ku CL*. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood. 2013, 121:1357-1366. 
  • von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, and Casanova JL. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008, 321:691-696.
  • Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, Chrabieh M, Issekutz AC, Cunningham CK, Gallin J, Holland SM, Roifman C, Ehl S, Smart J, Tang M, Barrat FJ, Levy O, McDonald D, Day-Good NK, Miller R, Takada H, Hara T, Al-Hajjar S, Al-Ghonaium A, Speert D, Sanlaville D, Li X, Geissmann F, Vivier E, Marodi L, Garty BZ, Chapel H, Rodriguez-Gallego C, Bossuyt X, Abel L, Puel A, and Casanova JL. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med. 2007, 204:2407-2422.
  • von Bernuth H, Ku CL*, Rodriguez-Gallego C, Zhang S, Garty BZ, Marodi L, Chapel H, Chrabieh M, Miller RL, Picard C, Puel A, and Casanova JL. A fast procedure for the detection of defects in Toll-like receptor signaling. Pediatrics. 2006, 118:2498-2503.
  • Ku CL, Dupuis-Girod S, Dittrich AM, Bustamante J, Santos OF, Schulze I, Bertrand Y, Couly G, Bodemer C, Bossuyt X, Picard C, and Casanova JL. NEMO mutations in 2 unrelated boys with severe infections and conical teeth. Pediatrics. 2005, 115:e615-619.
  • Ku CL, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, Lawrence T, Chang HH, Al-Mousa H, Picard C, and Casanova JL. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev. 2005, 203:10-20.
  • Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, and Casanova JL. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003, 299:2076-2079.